3928 Point Eden Way
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. Arcus has several programs targeting important oncology/immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small molecule inhibitor of CD73, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, oncology, immunology, biochemistry, pharmacology and structural biology. Utilizing these unique capabilities, Arcus has developed a robust and active early stage discovery effort focused on small-molecule pipeline expansion.
Stock Symbol: RCUS
Stock Exchange: NYSE
3 jobs with Arcus Biosciences
Arcus Biosciences is seeking a clinical biostatistician with broad responsibility for providing high-quality statistical expertise to assigned clin...
The Associate Director/Director of Statistical Programming will be responsible for the production of both formal and exploratory statistical output...
Overall Description The Clinical Scientist will be an essential contributor to the scientific, clinical, and operational scope of clinical develo...